David E. I. Pyott David E. I. Pyott, former Chairman and CEO of Allergan, Inc., was appointed to Tarsus Pharmaceuticals' Board of Directors. IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors. “David is one of the most accomplished leaders in eye care, with a strong track r ...

IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23, 2026 to report its fourth quarter and full year 2025 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About ...

Core Viewpoint - Tarsus Pharmaceuticals, Inc. (TARS) is experiencing significant selling pressure, with a 16.4% decline over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, supported by positive earnings forecasts from Wall Street analysts [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold conditions, with a reading below 30 indicating a stock may be oversold [2]. - TARS has an RSI reading of 19.34, suggesting that the heavy selling may be exhausting, indicating a potential bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts to raise earnings estimates for TARS, with a 15.5% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [7]. - TARS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8].

Core Insights - BioMarin Pharmaceutical (BMRN) has a Zacks Rank of 2 (Buy), indicating a stronger earnings outlook compared to Tarsus Pharmaceuticals, Inc. (TARS), which has a Zacks Rank of 3 (Hold) [3] - Value investors utilize various metrics to identify undervalued companies, including P/E ratio, P/S ratio, earnings yield, and cash flow per share [4] Valuation Metrics - BMRN has a forward P/E ratio of 10.82, significantly lower than TARS's forward P/E of 71.71, suggesting BMRN is more attractively priced [5] - The PEG ratio for BMRN is 0.54, while TARS has a PEG ratio of 1.26, indicating BMRN's expected earnings growth is more favorable [5] - BMRN's P/B ratio stands at 1.83, compared to TARS's P/B of 9.57, further highlighting BMRN's relative valuation strength [6] Value Grades - BMRN holds a Value grade of A, while TARS has a Value grade of D, indicating BMRN is viewed as the superior value investment based on earnings outlook and valuation metrics [6]

Core Insights - Tarsus Pharmaceuticals, Inc. (TARS) has been highlighted as a Buy due to the rapid commercialization of its product Xdemvy following FDA approval in July 2023, leading to a significant appreciation in stock value [1] Company Overview - Tarsus Pharmaceuticals is focused on the biotechnology sector, particularly in the development and commercialization of innovative therapies [1] - The company has successfully transitioned from a startup to a significant player in the pharmaceutical industry, with major investments received during its early stages [1] Product Development - Xdemvy received FDA approval in July 2023, which has catalyzed its commercialization efforts [1] - The rapid uptake of Xdemvy in the market is a key driver for Tarsus Pharmaceuticals' stock performance [1] Market Performance - Following the FDA approval of Xdemvy, Tarsus Pharmaceuticals' stock has appreciated significantly, indicating positive market reception and investor confidence [1]

Core Viewpoint - Tarsus Pharmaceuticals, Inc. (TARS) is highlighted as a Buy due to the rapid commercialization of its product Xdemvy following FDA approval in July 2023, leading to a significant appreciation in stock value since the recommendation [1]. Company Background - Tarsus Pharmaceuticals was founded by an individual with a Ph.D. in organic synthesis from Stanford University and has experience working for major pharmaceutical companies and biotech startups [1]. Stock Performance - The stock of Tarsus Pharmaceuticals has appreciated significantly since the recommendation was made in March 2023, indicating positive market reception and investor confidence in the company's future prospects [1].

Summary of Tarsus Pharmaceuticals FY Conference Call Company Overview - **Company**: Tarsus Pharmaceuticals (NasdaqGS:TARS) - **Core Product**: XDEMVY for Demodex blepharitis - **Pipeline**: Includes treatments for ocular rosacea and a potential prophylactic for Lyme disease Financial Performance - **Q3 Revenue**: Approximately $119 million, with 103,000 bottles dispensed [2][3] - **Q4 Guidance**: Expected revenue between $140-$145 million, leading to total annual revenue of $440-$445 million for the year [3][20] - **DTC Campaign**: Successfully driving growth, with over 90% payer coverage achieved [5][11] Market Dynamics - **Sales Strategy**: Focus on educating eye care professionals (ECPs) about identifying Demodex blepharitis in patients, including those who are asymptomatic [4][5] - **Physician Engagement**: Over 20,000 ECPs have prescribed XDEMVY, with efforts to convert occasional prescribers into regular ones [7][8] - **Payer Relations**: Strong initial education efforts have led to good payer coverage, with no anticipated pushback from payers [11][20] Product Insights - **Efficacy**: 85% of patients reported clinically meaningful benefits from XDEMVY [9] - **Retreatment Rates**: Expected baseline retreatment rate of 20%, with current mid-teen rates observed in older cohorts [17][18] - **Seasonality**: Anticipated fluctuations in prescription volumes due to holidays and office closures [25] Future Outlook - **Ocular Rosacea Program**: Phase two study expected to start by the end of 2025, with top-line data anticipated in the second half of 2026 [46][48] - **Lyme Disease Program**: Oral prophylactic treatment showing promise, with a tick kill study indicating 98% efficacy [56][57] - **Financial Position**: Well-capitalized with approximately $400 million available for future investments and potential partnerships [59] Strategic Considerations - **Guidance Changes**: Transitioning to revenue guidance for 2026 based on improved understanding of market dynamics and DTC impact [32][33] - **Sales Force Utilization**: Plans to leverage the existing sales force for potential new products and partnerships in the future [60] Additional Notes - **Market Education**: Continuous efforts to educate both physicians and patients about Demodex blepharitis and ocular rosacea are crucial for driving adoption [39][51] - **Regulatory Feedback**: Positive feedback from the FDA regarding endpoints for ocular rosacea studies, focusing on patient-reported outcomes [41][42]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

分组1 - Tarsus Pharmaceuticals reported a quarterly loss of $0.3 per share, which was better than the Zacks Consensus Estimate of a loss of $0.35, and an improvement from a loss of $0.61 per share a year ago, resulting in an earnings surprise of +14.29% [1] - The company achieved revenues of $118.7 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 2.80%, and showing significant growth from $48.12 million in the same quarter last year [2] - Tarsus Pharmaceuticals has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has increased approximately 26% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.10 on revenues of $127.92 million, and for the current fiscal year, it is -$1.62 on revenues of $428.6 million [7] - The Medical - Biomedical and Genetics industry, to which Tarsus Pharmaceuticals belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Financial Data and Key Metrics Changes - In Q3 2025, Tarsus Pharmaceuticals reported approximately $119 million in net revenue, reflecting a significant increase from the previous quarter, with over 103,000 bottles of XDEMVY delivered to patients [3][10][15] - The company achieved a gross to net discount of 44.7%, consistent with previous guidance, driven by adjustments related to the Medicare Manufacturers Discount Program and an increase in Medicare patients entering the catastrophic coverage category [16][17] - For Q4, Tarsus expects net product sales for XDEMVY to be in the range of $140 million to $145 million, contributing to an annual revenue forecast of $440 million to $445 million [17][19] Business Line Data and Key Metrics Changes - XDEMVY has become one of the best-selling prescription eye drops, with over 20,000 doctors prescribing it, and a 20% increase in weekly prescribers noted [4][10][11] - The refill rate for prescriptions is showing positive trends, with over 10% of weekly prescriptions being refills, and expectations for this to stabilize around 20% over time [13][35] Market Data and Key Metrics Changes - The company is experiencing a positive trend in direct-to-consumer (DTC) engagement, with a 90% increase in website visits and a 42% growth in unaided awareness since the last quarter [12][60] - Tarsus is seeing strong adoption across multiple patient segments, particularly in the treatment of Demodex blepharitis, which is now recognized as a mainstream condition [13][14] Company Strategy and Development Direction - Tarsus aims to broaden its pipeline and expand globally, with plans to initiate a phase two trial for ocular rosacea by the end of the year and to advance its Lyme disease prevention program [8][18] - The company is focused on creating a market and shifting physician behavior to establish XDEMVY as a standard treatment in eye care [9][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing growth trajectory of XDEMVY, anticipating continued momentum into 2026 and beyond, with a clear path to achieving Blockbuster Plus potential [19][20] - The management team highlighted the importance of physician education and patient engagement in driving the adoption of XDEMVY [35][56] Other Important Information - Tarsus is evaluating strategic options for its pipeline programs, including potential partnerships to advance its Lyme disease program efficiently [18] - The company is also considering flexible commercial strategies for international markets, particularly in Europe and Japan [18][19] Q&A Session Summary Question: Changes in doctors' practice patterns regarding XDEMVY - Management noted a significant increase in the depth of prescribing, with a 20% rise in weekly prescribers and a 30% increase in those prescribing multiple times a week, driven by new data on meibomian gland disease [25][27][29] Question: Refill rates and patient return behavior - The company reported a positive trend in refill rates, with over 10% of weekly prescriptions being refills, and emphasized the importance of physician education on the chronic nature of the disease to encourage patient follow-ups [33][35] Question: Update on peak sales estimates for XDEMVY - Management indicated that while they are thrilled with current performance, they are not ready to quantify peak sales estimates but continue to believe in the Blockbuster Plus potential of XDEMVY [33][39] Question: Status of TP-04 study for ocular rosacea - The company confirmed that no further FDA meeting is needed before starting the TP-04 trial, which is on track to begin later this year [43][44] Question: Insights on operational spending for 2026 - Management expects operational expenses to align with 2025 levels, with a focus on DTC spending and potential costs associated with the ocular rosacea and Lyme disease programs [45][46] Question: Traction between optometrists and ophthalmologists - Tarsus sees a balanced mix of prescriptions from both optometrists and ophthalmologists, with approximately 65% of volume coming from optometry, and both groups are showing strong engagement with XDEMVY [75][78]